Clinical Trial Update: SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors [NA]

View source ↗

Summary

Clinical trial update on SY001, a mesothelin-targeting therapy, tested in a single-arm, dose-escalation study in subjects with advanced solid tumors. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SY001

Snippet

Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd. | Conditions: Treatment Related Cancer, Ovarian Cancer | NA | Status: RECRUITING